Cardiology prior authorization at Humana
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Humana cardiology PA at a glance
Humana reviews cardiology PA submissions against its medical policy library, with rules drawn primarily from ACC/AHA Joint Guidelines + ESC equivalents for international references. Humana-specific context: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.
Documentation packet — what to send
- Diagnosis with ICD-10 (HF with reduced/preserved EF, ATTR-CM, ASCVD)
- Most recent echocardiogram with EF, strain, valvular function
- LDL on maximally-tolerated statin (for PCSK9)
- BNP/NT-proBNP
- Documented adverse effect or contraindication to step-therapy alternatives
Common denial patterns to pre-empt
Patterns observed in cardiology across payers, and where Humana's book of business overlaps:
- PCSK9 inhibitors: LDL threshold + maximally-tolerated statin not met
- Tafamidis: ATTR-CM diagnosis not confirmed by scintigraphy or biopsy
- Entresto: NYHA II-IV with reduced EF documentation missing
- Anticoagulant DOAC vs warfarin step therapy
- MA plan step therapy on Part B drugs
Appeal angles when Humana denies
- ACC/AHA guideline class I recommendation citation
- Cardiovascular outcome trial (FOURIER, PARADIGM-HF, EMPEROR, DAPA-HF) by name
- Imaging or biomarker evidence (BNP, ejection fraction, scintigraphy grade)
- Statin intolerance documentation per NLA Position Paper
Peer-to-peer prep
- Have echo with EF and the latest LDL panel open
- Quote the guideline Class I recommendation with reference number
- For PCSK9: explicitly state 'maximally tolerated statin' — payers reject 'tried and failed' wording
- For ATTR-CM: confirm whether the diagnosis was scintigraphy-based or biopsy-based — affects PA criteria
Drug-specific PA criteria at Humana
Deep dives on each drug's PA criteria at Humana:
Frequently asked questions
What documentation does Humana need for cardiology prior authorizations?
Humana's PA packet for cardiology typically includes: Diagnosis with ICD-10 (HF with reduced/preserved EF, ATTR-CM, ASCVD); Most recent echocardiogram with EF, strain, valvular function; LDL on maximally-tolerated statin (for PCSK9); BNP/NT-proBNP. ACC/AHA Joint Guidelines + ESC equivalents for international references citations strengthen the submission.
What's the turnaround at Humana?
Humana standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Medicare Advantage extension rule under 42 CFR Part 422 may add 14 days. Internal appeal window if denied: 60 days.
Which cardiology drugs does Humana most often PA-restrict?
Top targets in cardiology: apixaban, rivaroxaban, evolocumab, sacubitril valsartan, tafamidis. Each follows the per-drug step therapy + documentation requirements published in Humana's medical policy library.
How do I prep a peer-to-peer with Humana in cardiology?
Have echo with EF and the latest LDL panel open Quote the guideline Class I recommendation with reference number Have the policy URL and the patient's chart open before the call.
Generate a Cardiology PA packet
Open ApprovalHelp — generate a cardiology PA packet tailored to Humana's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com